Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Learn more about:
Related Clinical Trial
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Early Detection of Epstein-Barr Virus Related Disease.
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
Cellular Immunotherapy for Viral Induced Cancer – EBV Positive Lymphomas
Bortezomib Plus Rituximab for EBV+ PTLD
Risk Stratified Sequential Treatment for CD20-positive PTLD
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy